The current financial score of Aytu Biopharma Inc is 7.23. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 16.11M, representing a year-over-year increase of 6.42%, while its net profit experienced a year-over-year increase of 99.92%.
The current valuation score of Aytu Biopharma Inc is 8.74. Its current P/E ratio is -0.40, which is -3363.91% below the recent high of 12.96 and -438.28% above the recent low of -2.14.
The current earnings forecast score of Aytu Biopharma Inc is 8.00. The average price target is 9.67, with a high of 15.00 and a low of 7.00.
The current price momentum score of Aytu Biopharma Inc is 3.97. Currently, the stock price is trading between the resistance level at 2.06 and the support level at 1.67, making it suitable for range-bound swing trading.
The current institutional shareholding score of Aytu Biopharma Inc is 3.00. The latest institutional shareholding proportion is 36.10%, representing a quarter-over-quarter increase of 4.82%.
The current risk assessment score of Aytu Biopharma Inc is 4.02. The company's beta value is 0.24. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.